Please assess the completion status of the following clinical trial:

Trial Title: Desmoteplase in Acute Ischemic Stroke (DIAS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* scoring 4 to 20 on the National Institute of Health Stroke Scale (NIHSS)~* showing a perfusion-diffusion mismatch on MRI of 20 %~* enrolment within a 3 h to 9 h time window after symptom onset.~* 18-85 years of age~Exclusion Criteria:~* Participation in any interventional trial in the previous 30 days.~* Women in the childbearing age.~* Any history of intracranial hemorrhage, subarachnoid hemorrhage, neoplasm, arteriovenous malformation or aneurysm.~* Conditions that, according to the judgment of the investigator, might impose an additional risk to any individual stroke patient when receiving study medication (this applied to patients on platelet-function inhibitors as well).~* MRI exclusion criteria: Evidence of ICH, Evidence of SAH, Signs of extensive early infarction on DWI assessed by evidence of involvement of \>1/3 of the middle cerebral artery (MCA) territory. No perfusion deficit, Internal carotid artery (ICA) occlusion ipsilateral to stroke lesion without additional ipsilateral MCA, anterior cerebral artery (ACA) or posterior cerebral artery (PCA) occlusion. Any intracranial pathology that would interfere with the MRI assessment of acute ischemic stroke.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Desmoteplase 62.5 µg/kg BW i.v. bolus
- 2 (Type: ACTIVE_COMPARATOR): Desmoteplase 90 µg/kg BW i.v. bolus
- 3 (Type: ACTIVE_COMPARATOR): Desmoteplase 125 µg/kg BW i.v. bolus
- 4 (Type: PLACEBO_COMPARATOR): Placebo i.v. bolus

Based on this trial design, predict the completion outcome and termination type (if applicable).